Remsima (a Tumor Necrosis Factor (TNF) - α Inhibitor) induced hemolysis in a patient with Crohn's disease - Case report

CONCLUSION: Although cross-reactivity is expected between one biological agent to another, in our case the use of Adalimumab as alternative choice post Tumor necrosis factor Inhibitor (TNF) -α (Remsima infliximab) induced hemolysis did not cause hemolysis or any type of reaction.PMID:34484733 | PMC:PMC8403549 | DOI:10.1016/j.amsu.2021.102768

Source: Annals of Medicine - September 6, 2021 Category: Internal Medicine Authors: Rehab Y Al-Ansari Arwa Al Khuraim Leena Abdalla Hind Hamid N Y Zakary Source Type: research